Shares of XBiotech Inc. (NASDAQ:XBIT - Get Free Report) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $3.17 and traded as low as $2.80. XBiotech shares last traded at $2.87, with a volume of 37,766 shares trading hands.
XBiotech Price Performance
The company has a market cap of $89.02 million, a price-to-earnings ratio of -2.70 and a beta of 1.28. The business's fifty day moving average price is $3.16 and its 200 day moving average price is $4.65.
XBiotech (NASDAQ:XBIT - Get Free Report) last announced its earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter.
Institutional Trading of XBiotech
Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its holdings in XBiotech by 68.2% during the 4th quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company's stock worth $58,000 after purchasing an additional 5,930 shares during the last quarter. Virtu Financial LLC bought a new position in XBiotech during the fourth quarter worth $58,000. Bank of America Corp DE raised its stake in XBiotech by 42.0% during the fourth quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company's stock worth $79,000 after buying an additional 5,887 shares during the last quarter. Jane Street Group LLC bought a new stake in XBiotech during the third quarter valued at $86,000. Finally, Barclays PLC boosted its position in XBiotech by 13.9% during the fourth quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company's stock valued at $119,000 after acquiring an additional 3,661 shares during the last quarter. 55.70% of the stock is currently owned by institutional investors.
XBiotech Company Profile
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Further Reading
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
